GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium
June 10 2021 - 11:00AM
via NewMediaWire --
GeoVax Labs,
Inc. (Nasdaq: GOVX), a biotechnology company
developing human immunotherapies and vaccines against infectious
diseases and cancers, announced today that it will be participating
in the Alliance Global Partners’ Virtual Healthcare Symposium being
held on Thursday, June 17, 2021.
During the event, the GeoVax management team will
be conducting 1-on-1 investor meetings as part of the
symposium. To request a meeting with management or for more
information about the symposium, please contact AGP Events
at agpevents@allianceg.com.
About GeoVax
GeoVax is a clinical-stage company developing
vaccines against infectious diseases and cancer. GeoVax’s current
development programs are focused on preventive vaccines against
COVID-19, Zika Virus, hemorrhagic fever viruses (Ebola, Lassa,
Marburg and Sudan), HIV and malaria, as well as therapeutic
vaccines against multiple cancers.
Through the Company’s novel Modified Vaccinia
Ankara-Virus Like Particle (MVA-VLP) based platform, MVA, a large
virus capable of carrying multiple vaccine antigens, expresses
proteins that assemble into VLP immunogens within the person
receiving the vaccine. The production of VLPs in vivo mimics virus
production in a natural infection, stimulating both the humoral and
cellular arms of the immune system to recognize, prevent, and
control the target infection. The MVA-VLP derived vaccines elicit
durable immune responses in the host similar to a live-attenuated
virus, while providing the safety characteristics of a
replication-defective vector.
GeoVax Labs,
Inc.678-384-7220investor@geovax.com
GeoVax Labs (NASDAQ:GOVX)
Historical Stock Chart
From Mar 2024 to Apr 2024
GeoVax Labs (NASDAQ:GOVX)
Historical Stock Chart
From Apr 2023 to Apr 2024